- Adjusted EPS: $1.96, beating the estimate of $1.69
- Net Sales: $5.03 billion, a 2% decrease year-over-year, below the estimate of $5.09 billion
- Personal Care Net Sales: $2.69 billion, a 0.3% increase year-over-year, slightly below the estimate of $2.7 billion
- Consumer Tissue Net Sales: $1.49 billion, a 4.1% decrease year-over-year, just below the estimate of $1.5 billion
- K-C Professional Net Sales: $841 million, a 5.2% decrease year-over-year, below the estimate of $856.7 million
- Corporate & Other Net Sales: $10 million, a 23% decrease year-over-year, lower than the estimate of $12.7 million
- Organic Sales Growth: 4%, just short of the 5.11% estimate
- Personal Care Organic Sales Growth: 8%, slightly under the 8.64% estimate
- Consumer Tissue Organic Sales: down by 2%, missing the estimated growth of 1.48%
- Net Sales Volume Change: increased by 1%, beating the estimate of 0.82%
- Personal Care Net Sales Volume: increased by 3%, exceeding the estimate of 1.68%
- 2024 Outlook: Organic net sales expected to grow at mid-single digits
- Negative Impacts: Currency translation expected to negatively impact reported net sales by 400 basis points and divestitures by 120 basis points
- 2024 Adjusted EPS Growth: now expected to grow at a mid-to-high teens percentage rate on a constant-currency basis, up from previous low-teens growth expectations
- Currency Translation Impact: Reported operating profit and reported earnings per share expected to be negatively impacted by approximately 700 basis points
Kimberly Clark on Smartkarma
Analyst coverage of Kimberly Clark on Smartkarma by Baptista Research highlights the company’s performance and strategic moves. In the report titled “Kimberly-Clark Corporation: What Is Their New Operating Model And Will It Impact The Bottom-Line? – Major Drivers,” an optimistic outlook is presented for the company’s first quarter in 2024. Kimberly-Clark’s strategy of elevating categories with innovative products and expanding markets is driving positive results, with improvements in volume and a confident outlook on business momentum.
In another report by Baptista Research titled “Kimberly-Clark Corporation: Optimized Pricing and Volume Mix Strategy Could Be a Game Changer? – Major Drivers,” the focus is on the company’s growth trajectory amidst challenges. The strategy of elevating categories and expanding markets has shown promising outcomes, despite facing supply constraints that impacted market share. These reports provide valuable insights into Kimberly Clark‘s recent performances and strategic direction for future growth.
A look at Kimberly Clark Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Kimberly-Clark Corporation, a global health and hygiene company known for manufacturing consumer products like diapers, tissues, and paper towels, has received favorable Smart Scores in several key areas. With a solid Dividend score of 4 and a Momentum score of 4, the company appears to be in a good position to generate returns for investors and sustain its growth in the long run. While Value and Resilience scores are at 2, indicating room for improvement in these areas, Kimberly-Clark’s Growth score of 3 points towards potential for expanding its market presence.
Overall, Kimberly-Clark’s outlook based on the Smart Scores suggests a promising future, especially in terms of dividends and momentum. The company’s established global presence and diverse product line could contribute to its long-term success in meeting consumer demands and maintaining investor confidence. With a focus on enhancing its value and resilience factors, Kimberly-Clark may further solidify its position as a key player in the consumer products industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
